BROMPERIDOL DECANOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C31H41BrFNO3
Molecular Weight	574.565
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3

InChI

InChIKey=ZINCPWWBSRSXBH-UHFFFAOYSA-N

InChI=1S/C31H41BrFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

HIDE SMILES / InChI

Description
Sources: http://www.scbt.com/datasheet-210966-bromperidol.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/23152208 | https://www.ncbi.nlm.nih.gov/pubmed/15266450 | https://www.ncbi.nlm.nih.gov/pubmed/23343447

Bromperidol decanoate is a long-acting antipsychotic medication used in at least Belgium, Germany, Italy, and the Netherlands. In clinical trials, Bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The preparation seems to be less potent than other depot antipsychotics (such as fluphenazine and haloperidol decanoate) and better than placebo injection. If bromperidol decanoate is available to the clinician it may be a viable choice, especially when there are reasons not to use fluphenazine or haloperidol decanoate.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL339 Sources: https://www.jstage.jst.go.jp/article/jphs1951/69/4/69_4_399/_article	Antagonist 2778
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.genome.jp/dbget-bin/www_bget?D02626	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: http://www.mimaki-family-japan.com/products/detail.php?product_id=32440	Primary		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Clinical experiences in an open and a double-blind trial.	1978 Jan-Feb	347884
Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.	1978 Mar	643910
Clinical evaluation of bromperidol versus haloperidol in psychotic patients.	1980	7021451
Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.	1992 Nov	1487623
Possible interaction between cisapride and bromperidol.	1997 Jan	9075269
[Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].	1998 Feb	9592806
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.	2001 Apr 8	11353448
Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.	2002 Jan	11853119
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.	2003 Mar	12644990
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.	2004 Nov 26	15519367
Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians.	2007 Dec	19300635
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).	2008 Dec 22	19102734
Automated on-line in-tube solid-phase microextraction coupled with HPLC/MS/MS for the determination of butyrophenone derivatives in human plasma.	2009 Jun	19387622
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009 Oct 2	19798416
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Improvement of mutism in a catatonic schizophrenia case by add-on treatment with amantadine.	2010 Jun	20571993
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.	2011 Aug	21576426

Patents

Sample Use Guides

In Vivo Use Guide

Oral Schizophrenia: Adult: 1-15 mg daily, up to 50 mg daily. Intramuscular Schizophrenia: Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj. Intramuscular Psychoses: Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj. Oral Psychoses: Adult: 1-15 mg daily, up to 50 mg daily.

Route of Administration: Other

In Vitro Use Guide

Bromperidol is able to antagonize as well as haloperidol the DA-induced LH-RH release.

Name

Type

Language

BROMPERIDOL DECANOATE

Official Name

English

BROMPERIDOL DECANOATE [USP-RS]

Common Name

English

BROMPERIDOL DECANOATE [MART.]

Common Name

English

4-(4-(P-BROMOPHENYL)-4-HYDROXYPIPERIDINOL)-4'-FLUOROBUTYROPHENONE DECANOATE

Common Name

English

DECANOIC ACID, 4-(4-BROMOPHENYL)-1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-4-PIPERIDINYL ESTER

Common Name

English

R-46541

Code

English

BROMPERIDOL DECANOATE [EP MONOGRAPH]

Common Name

English

Bromperidol decanoate [WHO-DD]

Common Name

English

BROMPERIDOL DECANOATE (ESTER)

Common Name

English

BROMPERIDOL DECANOATE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710